Related Experiment Videos
Cyclooxygenase-2 biology.
1DNA Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona 08036, Spain. jclaria@clinic.ub.es
Current Pharmaceutical Design
|October 8, 2003
Summary
Selective COX-2 inhibitors offer anti-inflammatory benefits with reduced gastrointestinal risks. This review explores cyclooxygenase-2 (COX-2) in health, disease, and cancer therapy.
Area of Science:
- Biochemistry
- Pharmacology
- Cell Biology
Background:
- Eicosanoid biosynthesis begins with phospholipase A(2) releasing arachidonic acid.
- Cyclooxygenase (COX) enzymes convert arachidonic acid into prostaglandins (PGs) and thromboxanes (TX).
- The COX pathway is targeted by non-steroidal anti-inflammatory drugs (NSAIDs) for pain, fever, and inflammation relief.
Purpose of the Study:
- To review advancements in cyclooxygenase-2 (COX-2) and prostaglandin (PG) biosynthesis.
- To elucidate the role of COX-2 in various health and disease states.
- To discuss the therapeutic potential and unresolved issues of selective COX-2 inhibitors (COXIBs).
Main Methods:
- Literature review of COX-2 and PG biosynthesis research.
- Analysis of the role of COX-2 in inflammation, gastrointestinal integrity, and platelet aggregation.
- Examination of selective COX-2 inhibitors (COXIBs) and their clinical implications.
Main Results:
- COX-2 is primarily responsible for inflammation, unlike COX-1.
- Selective COX-2 inhibitors (COXIBs) demonstrate anti-inflammatory activity with lower gastrointestinal toxicity.
- COX-2 plays a role in inflammatory conditions and potentially in cancer development.
Conclusions:
- Selective COX-2 inhibitors represent a promising therapeutic strategy for inflammatory conditions.
- Further research is needed to address unresolved issues concerning the long-term safety and efficacy of COXIBs.
- COX-2 inhibition may offer novel therapeutic avenues for cancer treatment.